Comparative Pharmacology
Head-to-head clinical analysis: TAVIST ALLERGY SINUS HEADACHE versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAVIST ALLERGY SINUS HEADACHE versus TAVIST 1.
TAVIST ALLERGY/SINUS/HEADACHE vs TAVIST-1
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Temporary relief of symptoms associated with hay fever or other upper respiratory allergies (rhinitis, sinusitis)Temporary relief of sinus congestion and pressureTemporary relief of headache associated with allergy or sinus symptoms
Allergic rhinitisUrticariaAngioedemaAllergic conjunctivitis (off-label)
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Clemastine is metabolized via hepatic hydroxylation and demethylation; acetaminophen undergoes hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation; phenylpropanolamine is metabolized by hepatic deamination and oxidation.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4) and other unspecified pathways. Undergoes extensive first-pass metabolism.
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Clemastine: 95-99% bound to plasma proteins; pseudoephedrine: minimal binding (~10-20%); acetaminophen: 10-25% bound
~75% bound to plasma proteins (albumin).
Clemastine: 4-6 L/kg (extensive tissue distribution); pseudoephedrine: 2-3 L/kg; acetaminophen: 0.9 L/kg (total body water)
~2.5 L/kg; indicates extensive tissue distribution.
Oral: clemastine ~100%; pseudoephedrine ~100%; acetaminophen 60-90% (FDA range: 63-89%)
Oral: ~60–70% due to first-pass metabolism.
CrCl 10-50 mL/min: avoid or reduce frequency; CrCl <10 mL/min: contraindicated due to diphenhydramine accumulation and anticholinergic effects
CrCl <10 mL/min: not recommended; CrCl 10-30 mL/min: 1.34 mg every 12 hours; CrCl >30 mL/min: no adjustment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: cautious use (avoid >4 g/day acetaminophen); Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity risk
Child-Pugh A: no adjustment; Child-Pugh B: 1.34 mg every 12 hours; Child-Pugh C: not recommended.
Not recommended for children under 12 years; ages 12-17: same as adult dose
Children 6-11 years: 0.67 mg orally every 12 hours; children 12 years and older: adult dosing.
Avoid in patients ≥65 years due to diphenhydramine's anticholinergic effects (increased risk of confusion, falls, urinary retention). Alternative therapies recommended.
Initiate at 1.34 mg orally once daily; maximum 2.68 mg/day due to increased anticholinergic sensitivity.
None.
None
Risk of serious cardiovascular events (hypertension, arrhythmia, stroke) with phenylpropanolamine; avoid use in patients with heart disease, hypertension, thyroid disease, diabetes, or prostatic hypertrophy; may cause drowsiness; avoid alcohol; hepatotoxicity with acetaminophen overdose; do not exceed recommended dose.
Sedation and somnolence; avoid alcohol and other CNS depressants. Use with caution in patients with asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension, and prostatic hyperplasia. May impair mental alertness; caution when driving or operating machinery. Use in elderly or debilitated patients may increase risk of dizziness, sedation, and hypotension. Avoid in breastfeeding infants due to risk of anticholinergic effects.
Hypersensitivity to any component; patients taking MAO inhibitors or within 14 days of stopping; severe hypertension; coronary artery disease; narrow-angle glaucoma; urinary retention; concomitant use of other products containing acetaminophen.
Hypersensitivity to clemastine or any component of the formulation. Avoid in patients with severe liver disease, narrow-angle glaucoma, urinary retention, acute asthma attack, and during breastfeeding. Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy.
Data Pending Review
Data Pending Review
Avoid alcohol and caffeine-containing beverages. High-tyramine foods (e.g., aged cheese, cured meats) may increase pseudoephedrine pressor effect.
Avoid alcohol; may enhance sedative effects. No specific food restrictions, but taking with food may reduce GI upset.
Tavist Allergy/Sinus/Headache contains clemastine (antihistamine) and pseudoephedrine (decongestant). Clemastine: No adequate human studies; animal studies show no teratogenicity at therapeutic doses. Pseudoephedrine: Linked to gastroschisis in first trimester; avoid use. First trimester: Pseudoephedrine contraindicated due to possible vascular disruption. Second/third trimester: Clemastine is generally safe (Category B), but pseudoephedrine may cause fetal tachycardia and reduced uteroplacental blood flow; avoid near term.
Teratogenic risk profile for TAVIST-1 (clemastine fumarate) is based on limited human data. Animal studies have not shown teratogenic effects. In pregnant women, avoid use during first trimester due to theoretical risks; second and third trimester use is considered safer but only if clearly needed.
Clemastine: Excreted in breast milk; reported to cause drowsiness and irritability in infants. M/P ratio unknown. Pseudoephedrine: Excreted in breast milk, M/P ratio approximately 2.6-3.5; may cause irritability and sleep disturbances. Avoid breastfeeding due to potential adverse effects on the infant.
Clemastine is excreted in breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. Because of potential for adverse effects in nursing infants (such as drowsiness, irritability), use caution and consider alternatives, especially in preterm or low-birth-weight infants.
No specific pharmacokinetic data necessitate dose adjustment, but due to risks, use lowest effective dose for shortest duration. Clemastine clearance may increase in pregnancy; however, no dose change recommended. Pseudoephedrine: Avoid use; no safe dose established.
Pregnancy may alter pharmacokinetics of clemastine due to increased volume of distribution and metabolic rate, but specific dose adjustments have not been established. Use the lowest effective dose for the shortest duration. Avoid use in labor and delivery due to potential for neonatal respiratory depression.
Category C
Category C
Tavist Allergy/Sinus/Headache is a combination of clemastine (first-generation antihistamine), pseudoephedrine (decongestant), and acetaminophen (analgesic). Avoid in patients with hypertension, glaucoma, urinary retention, or MAOI use. Clemastine causes significant sedation; warn about driving. Pseudoephedrine can cause insomnia and tachycardia. Acetaminophen hepatotoxicity risk with >3 g/day or alcohol use.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine with significant anticholinergic properties. It is more sedating than second-generation agents. Onset of action is 30-60 minutes. Use with caution in elderly, glaucoma, urinary retention, and asthma. Avoid in patients with MAOI use within 14 days. May cause CNS depression with alcohol or other CNS depressants.
Do not take more than 6 tablets in 24 hours.Avoid alcohol and other sedatives due to additive drowsiness.Do not use if you have high blood pressure, glaucoma, or an enlarged prostate.Stop and consult a doctor if symptoms persist for more than 7 days.This product contains acetaminophen; do not combine with other acetaminophen-containing products.
Take exactly as directed; do not exceed recommended dose.May cause drowsiness; avoid driving or operating machinery until you know how it affects you.Do not drink alcohol or use other sedatives while taking this medication.Notify your doctor if you have glaucoma, difficulty urinating, or prostate problems.Store at room temperature away from moisture and heat.